share_log

The Past Five Years for Avanos Medical (NYSE:AVNS) Investors Has Not Been Profitable

The Past Five Years for Avanos Medical (NYSE:AVNS) Investors Has Not Been Profitable

Avanos Medical(紐約證券交易所代碼:AVNS)投資者在過去五年中一直沒有盈利
Simply Wall St ·  02/23 10:03

Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. For example the Avanos Medical, Inc. (NYSE:AVNS) share price dropped 58% over five years. We certainly feel for shareholders who bought near the top. We also note that the stock has performed poorly over the last year, with the share price down 33%.

一般而言,長期投資是必經之路。但在此過程中,一些股票將表現不佳。例如,阿瓦諾斯醫療公司(紐約證券交易所代碼:AVNS)的股價在五年內下跌了58%。對於在接近頂部買入的股東,我們當然有同感。我們還注意到,該股去年表現不佳,股價下跌了33%。

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

現在讓我們來看看公司的基本面,看看長期股東回報是否與基礎業務的表現相匹配。

Because Avanos Medical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

由於Avanos Medical在過去十二個月中出現了虧損,因此我們認爲至少目前市場可能更加關注收入和收入增長。一般而言,沒有利潤的公司預計每年收入將增長,而且速度很快。可以想象,收入的快速增長如果持續下去,通常會帶來利潤的快速增長。

In the last half decade, Avanos Medical saw its revenue increase by 2.5% per year. That's not a very high growth rate considering it doesn't make profits. It's likely this weak growth has contributed to an annualised return of 10% for the last five years. We want to see an acceleration of revenue growth (or profits) before showing much interest in this one. However, it's possible too many in the market will ignore it, and there may be an opportunity if it starts to recover down the track.

在過去的五年中,Avanos Medical的收入每年增長2.5%。考慮到它沒有盈利,這不是一個很高的增長率。這種疲軟的增長很可能使過去五年的年化回報率達到10%。在對此表現出濃厚興趣之前,我們希望看到收入(或利潤)的加速增長。但是,市場上可能有太多人會忽略它,如果它開始復甦,可能會有機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。

earnings-and-revenue-growth
NYSE:AVNS Earnings and Revenue Growth February 23rd 2024
紐約證券交易所:AVNS收益和收入增長 2024年2月23日

Take a more thorough look at Avanos Medical's financial health with this free report on its balance sheet.

通過這份免費的資產負債表報告,更全面地了解Avanos Medical的財務狀況。

A Different Perspective

不同的視角

While the broader market gained around 26% in the last year, Avanos Medical shareholders lost 33%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. You could get a better understanding of Avanos Medical's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

儘管去年整個市場上漲了約26%,但Avanos Medical的股東卻下跌了33%。即使是優質股票的股價有時也會下跌,但我們希望在過於感興趣之前看到企業基本指標的改善。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年中10%的年化虧損還要糟糕。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。通過查看這張更詳細的收益、收入和現金流歷史圖表,您可以更好地了解Avanos Medical的增長。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想與管理層一起購買股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論